Kodak (KODK) enters $100M ATM Equity Offering Sales Agreement

Kodak (NYSE: KODK) disclosed:

On May 21, 2025, Eastman Kodak Company (the “Company”) entered into an ATM Equity OfferingSM Sales Agreement (the “Sales Agreement”) with BofA Securities, Inc. (“BofA”), pursuant to which the Company may offer and sell up to $100,000,000 of shares of the Company’s common stock, par value $0.01 per share (the “shares”), from time to time, in “at-the-market” offerings through BofA, as sales agent or as principal (the “at-the-market program”). The Company intends to use the net proceeds from the sale of the shares for general corporate purposes.

Sales of the shares, if any, will be made at prevailing market prices at the time of sale, or as otherwise agreed with BofA. BofA will receive a commission from the Company that will not exceed, but may be lower than, 3% of the gross sales price of all shares sold under the Sales Agreement. Any shares will be issued pursuant to the Company’s shelf registration statement (Registration No. 333-281403) (the “Registration Statement”), which was filed with the Securities and Exchange Commission on August 8, 2024 and declared effective on August 21, 2024, as supplemented by the prospectus supplement, dated May 21, 2025.

The Company is not obligated to sell, and BofA is not obligated to buy or sell, any shares under the Sales Agreement, and no assurance can be given that the Company will sell any such shares, or, if it does, as to the price or amount of shares that it sells or the dates when such sales will take place. Under the Sales Agreement, the Company has agreed to indemnify BofA against certain liabilities, including under the Securities Act of 1933, as amended, or to contribute to payments that BofA may be required to make because of such liabilities.

The foregoing description of the Sales Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the agreement. Copies of the Sales Agreement and the opinion of Day Pitney LLP relating to the validity of the shares that may be sold pursuant to the Sales Agreement are attached hereto as Exhibit (1.1) and Exhibit (5.1), respectively, and are incorporated by reference herein and in the Registration Statement.

You May Also Be Interested In

• enVVeno Medical (NVNO) files $100M mixed shelf
• Silexion Therapeutics faces Nasdaq delisting over equity shortfall
• CoVolt Power files for proposed IPO